Looking back at earlier preliminary phase 1a data and found the...

Looking back at earlier preliminary phase 1a data and found the data presented to be useful when comparing CHM results to other drugs in development

The below slide showed the comparison against current drugs in development - not sure how these have progressed but worth looking into.

CHM trial all dose levels complete (n=11) DCR 55%



This slide form more recent presentation compare against current approved treatments



Most of the comments to date have been around CHM1101 compared to current approved treatments with CHM1101 stacking up pretty well. I think it's important to note that CHM1101 also stacks up well when compared to other drugs in development.